AMA submission to the TGA on updated therapeutic goods advertising code and guidelines

1 May 2018

The AMA supports, in principle, the changes proposed to the therapeutic goods advertising code because they will strengthen and clarify the advertising of therapeutic goods in a modern media environment. However, the draft guidelines circulated for public comment are incomplete in significant areas. The AMA also continues to oppose the default advertising of Schedule 3 medicines, especially given the intention to move to industry self-regulation.